<药品生产许可证>Zhitong Finance App News, Baiyunshan (00874.HK) issued an announcement. Recently, the Guangdong Drug Administration issued the “Guangdong Drug Administration's Notice on Cancellation (No. 102 of 2025)”. Guangzhou Baiyunshan Xingzhu Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. (hereinafter referred to as “Xingzhu Pharmaceutical”), has been cancelled. The reason for this cancellation is that Xingzhu Pharmaceutical has adjusted its production and operation business, and the scope of production is Chinese medicine tablets After the “Pharmaceutical Production License” expires, it will not be possible to apply for a new license.

Zhitong Finance App News, Baiyunshan (00874.HK) issued an announcement. Recently, the Guangdong Drug Administration issued the “Notice of Cancellation of the Guangdong Drug Administration (No. 102 of 2025)”. Guangzhou Baiyunshan Xingzhu Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Co., Ltd .<药品生产许可证> (hereinafter referred to as “Xingzhu Pharmaceutical”) “Pharmaceutical Production License” has been cancelled. The reason for this cancellation is that Xingzhu Pharmaceutical has adjusted its production and operation business, and the scope of production is Chinese medicine tablets After the “Pharmaceutical Production License” expires, it is not possible to apply for a new license.